Logo

New England BioLabs NEBNext Direct Custom Ready Panels

Jul 10, 2018

New England Biolabs has launched the NEBNext Direct Custom Ready Panels, which allow users to design customized panels from a library of pre-synthesized baits for about 850 genes associated with a number of human diseases. The panels use the NEBNext Direct target enrichment technology, which hybridizes genomic DNA with biotinylated probes and converts the captured molecules into sequence-ready libraries. A unique molecular identifier tag is added to each DNA molecule prior to the final PCR amplification step. New England Biolabs said it will periodically update the panels to add new genes to the list and will update content corresponding to changes in gene definition and coordinates.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.